Multicenter phase II study of S-1 plus Weekly Cisplatin in first-line treatment of unresectable or reccurent gastric cancer
Phase 2
- Conditions
- gastric cancer
- Registration Number
- JPRN-UMIN000001858
- Lead Sponsor
- Tsukuba Cancer Clinical Trial Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1)Serious drug hypersensitivity or a history of drug allergy 2)Administered of flucytosine, phenytoin or warfarin potassium 3)Active infections 4)Serious complications (e.g., interstitial pneumonitis, pulmonary fibrosis, uncontrolled diabetes mellitus, renal failure or hepatic failure) 5)Uncontrolled watery diarrhea 6)Severe ascites or pleural effusion 7)Active double cancer 8)Pregnant women, possibly pregnant women, women wishing to become pregnant, and nursing mothers 9)Men who are currently attempting to conceive children 10)Judged ineligible for participation in the study by the investigator for safety reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1-year survival rate
- Secondary Outcome Measures
Name Time Method Adverse event rate, Progression free survival, Overall survival, Time to treatment failure